Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Abstract With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luis M. A. Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A. Lashuel, David Sulzer, Kostas Vekrellis, Glenda M. Halliday, Julianna J. Tomlinson, Michael Schlossmacher, Poul Henning Jensen, Julia Schulze-Hentrich, Olaf Riess, Warren D. Hirst, Omar El-Agnaf, Brit Mollenhauer, Peter Lansbury, Tiago F. Outeiro
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/78fcd2512d1c4506897e5895f2a201f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78fcd2512d1c4506897e5895f2a201f4
record_format	dspace
spelling	oai:doaj.org-article:78fcd2512d1c4506897e5895f2a201f42021-12-02T16:13:46ZAlpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease10.1038/s41531-021-00203-92373-8057https://doaj.org/article/78fcd2512d1c4506897e5895f2a201f42021-07-01T00:00:00Zhttps://doi.org/10.1038/s41531-021-00203-9https://doaj.org/toc/2373-8057Abstract With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.Luis M. A. OliveiraThomas GasserRobert EdwardsMarkus ZweckstetterRonald MelkiLeonidas StefanisHilal A. LashuelDavid SulzerKostas VekrellisGlenda M. HallidayJulianna J. TomlinsonMichael SchlossmacherPoul Henning JensenJulia Schulze-HentrichOlaf RiessWarren D. HirstOmar El-AgnafBrit MollenhauerPeter LansburyTiago F. OuteiroNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 7, Iss 1, Pp 1-23 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Luis M. A. Oliveira Thomas Gasser Robert Edwards Markus Zweckstetter Ronald Melki Leonidas Stefanis Hilal A. Lashuel David Sulzer Kostas Vekrellis Glenda M. Halliday Julianna J. Tomlinson Michael Schlossmacher Poul Henning Jensen Julia Schulze-Hentrich Olaf Riess Warren D. Hirst Omar El-Agnaf Brit Mollenhauer Peter Lansbury Tiago F. Outeiro Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
description	Abstract With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
format	article
author	Luis M. A. Oliveira Thomas Gasser Robert Edwards Markus Zweckstetter Ronald Melki Leonidas Stefanis Hilal A. Lashuel David Sulzer Kostas Vekrellis Glenda M. Halliday Julianna J. Tomlinson Michael Schlossmacher Poul Henning Jensen Julia Schulze-Hentrich Olaf Riess Warren D. Hirst Omar El-Agnaf Brit Mollenhauer Peter Lansbury Tiago F. Outeiro
author_facet	Luis M. A. Oliveira Thomas Gasser Robert Edwards Markus Zweckstetter Ronald Melki Leonidas Stefanis Hilal A. Lashuel David Sulzer Kostas Vekrellis Glenda M. Halliday Julianna J. Tomlinson Michael Schlossmacher Poul Henning Jensen Julia Schulze-Hentrich Olaf Riess Warren D. Hirst Omar El-Agnaf Brit Mollenhauer Peter Lansbury Tiago F. Outeiro
author_sort	Luis M. A. Oliveira
title	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
title_short	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
title_full	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
title_fullStr	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
title_full_unstemmed	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
title_sort	alpha-synuclein research: defining strategic moves in the battle against parkinson’s disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/78fcd2512d1c4506897e5895f2a201f4
work_keys_str_mv	AT luismaoliveira alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT thomasgasser alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT robertedwards alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT markuszweckstetter alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT ronaldmelki alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT leonidasstefanis alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT hilalalashuel alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT davidsulzer alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT kostasvekrellis alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT glendamhalliday alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT juliannajtomlinson alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT michaelschlossmacher alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT poulhenningjensen alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT juliaschulzehentrich alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT olafriess alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT warrendhirst alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT omarelagnaf alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT britmollenhauer alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT peterlansbury alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease AT tiagofouteiro alphasynucleinresearchdefiningstrategicmovesinthebattleagainstparkinsonsdisease
_version_	1718384357859655680

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Ejemplares similares